Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study
SPRINT-MS investigators
Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
Institute of Clinical and Translational Sciences (ICTS)
Section of Multiple Sclerosis & Neuroimmunology
Research output
:
Contribution to journal
›
Article
›
peer-review
36
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Sclerosis
100%
Ibudilast
100%
Systolic Blood Pressure Intervention Trial (SPRINT)
100%
Placebo
45%
T2 Lesions
36%
Hypointense Lesions
27%
Gray Matter Atrophy
27%
Image Evaluation
18%
Atrophy
18%
Progressive multiple Sclerosis
18%
Brain Volume
18%
Structural Image
18%
Whole Brain Atrophy
18%
Non-associated
9%
Randomized Placebo-controlled Trial
9%
Inflammatory Process
9%
New Lesion
9%
Sensitivity Analysis
9%
Blinded Study
9%
Progressive Form
9%
Neurodegenerative Processes
9%
T1 Hypointensity
9%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Ibudilast
100%
Placebo
54%
Brain Atrophy
18%
Inflammation
9%